DENVER, March 9 /PRNewswire-FirstCall/ -- Myogen, Inc. (Nasdaq: MYOG)
announced today that Michael J. Valentino has been appointed to the Company's
Board of Directors. Mr. Valentino is President and Chief Executive Officer of
Adams Respiratory Therapeutics.
"We are extremely pleased that Michael has agreed to join the Myogen Board
of Directors," stated J. William Freytag, President and CEO of Myogen. "He
brings nearly 30 years experience in the prescription and consumer
pharmaceuticals industry to help guide Myogen's future growth. We believe he
will be a great asset to the Company's Board and its stockholders."
Prior to joining Adams Respiratory Therapeutics, Mr. Valentino served as
President and Chief Operating Officer of Alpharma, a large global generic
pharmaceutical company. Prior to joining Alpharma, he served in senior
management roles at Novartis AG, including as the Executive Vice President,
Global Head Consumer Pharmaceuticals and the President and Chief Operating
Officer of Novartis Consumer Healthcare, North America. From 1996 to 1998,
Mr. Valentino served as the President of Pharmacia & Upjohn's Consumer
Products Division. Prior to 1996, Mr. Valentino spent 12 years at Warner
Lambert in a variety of senior level roles, including Vice President,
Corporate Strategic Planning; Vice President, Eastern Business Unit (Parke
Davis Pharmaceuticals); and Vice President, Worldwide Smoking Cessation.
About Myogen
Myogen is a biopharmaceutical company focused on the discovery,
development and commercialization of small molecule therapeutics for the
treatment of cardiovascular disorders. Myogen currently markets one product
in Europe for the treatment of acute decompensated heart failure and has three
product candidates in late-stage clinical development: enoximone capsules for
the treatment of patients with advanced chronic heart failure, ambrisentan for
the treatment of patients with pulmonary arterial hypertension and darusentan
for the treatment of patients with resistant systolic hypertension. The
company, in conjunction with Novartis, also conducts a target and drug
discovery research program focused on the development of disease-modifying
drugs for the treatment of chronic heart failure and related cardiovascular
disorders. Please visit our website at http://www.myogen.com.
SOURCE Myogen, Inc.
 back to top
Related links:
http://www.myogen.com
CONTACT:
Derek K. Cole, Director, Investor Relations
of Myogen, Inc., +1-303-464-3986, derek.cole@myogen.com
|
